KRAS is one of the most frequently activated oncogenes in human cancers. While the role of KRAS mutation in tumorigenesis and tumor maintenance has been extensively studied, the relationship between ...

Share on Pinterest New research shows certain KRAS mutations in pancreatic cancer may improve survival rates compared to other mutations. William Taufic/Getty Images In 2020, more than 495,000 adults ...

July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...

U.K.-based AstraZeneca has scored the exclusive rights to develop and commercialize the pan-KRAS inhibitor, dubbed JAB-23E73, outside China. On Jacobio’s home territory, the Beijing-headquartered ...

Investigators in Sweden recently examined how KRAS mutations impact overall survival (OS) in a population of patients with stage IV NSCLC. Among patients who received ICB, those with KRAS mutations ...

Pelareorep (Reolysin), an intravenously delivered oncolytic virus immunotherapy, has demonstrated positive second-line ...

Dr Sabari highlights typical outcomes for patients with NSCLC vs KRAS G12C-mutated NSCLC, as well as challenges associated with targeted treatments. One of the key problems with identifying and acting ...

Different Kirsten rat sarcoma virus (KRAS) mutations in pancreatic ductal adenocarcinoma show varying treatment responses, with G12D and G12V mutations linked to worse outcomes compared with wild type ...

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...

Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...